working
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it's great news, no buts ...
I agree, but many vaccinated people equal less infected people
Exactly, or you go with a big one or ...
Pfizer Says Its Covid-19 Vaccine Is "90% Effective" According To First Phase 3 Results
rising in premarket + 13%, a joy to the world
excellent explanation, thanks
back to the starting point,
as every time we have news, we have returned to the starting price in just a few days,
I do not understand, no matter how much manipulation exists, we cannot raise a single cent with this news
"Acorda, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $53.09 million for the quarter ended September 2020, surpassing the Zacks Consensus Estimate by 80.64%. This compares to year-ago revenues of $47.72 million. The company has topped consensus revenue estimates three times over the last four quarters."
Acorda Therapeutics (ACOR) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.46 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 23.33%. A quarter ago, it was expected that this drugmaker would post a loss of $0.46 per share when it actually produced a loss of $0.35, delivering a surprise of 23.91%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
"We ended the third quarter with cash, cash equivalents, investments and restricted cash of $ 101.3 million. Please note that, as we previously reported, in July we received a $ 12.7 million tax refund under the CARES Act, which allowed us to carry over 2019 net operating losses to prior tax years, resulting in the refund; this amount is included in our cash balance at the end of the quarter. Also, as I mentioned earlier, in the third quarter, we achieved a $ 15 million milestone payment from Biogen."
more cash than market value ...
first, 16 million in tax refund, second, contract with VA, third 15 million from Biogen ... today 10Q after hours
you mean 300.000 in the BID at 23?
I agree, or BP or nothing
I agree, first 1$...
https://www.nature.com/articles/s41587-020-0692-z
"Dry powders are emerging as an alternative to aerosol delivery for inhalation. Acorda Therapeutics has a delivery platform based on dry powder inhalation. Acorda CEO Ron Cohen says their approach is to engineer powdered granules that resemble Wiffle balls. “There’s a lot of surface area because of all of the curves, so even a slight breeze, a slight breath is going to spin it. Just a regular, easy inhalation can get large amounts of the drug in.” Acorda’s pipeline does not include any nucleic acid therapeutics — it markets Inbrija, a levodopa inhalation powder for Parkinson’s disease — but the company’s chief medical officer, Burkhard Blank, says the technical aspects of designing a dry powder formulation should be similar. Blank says that Acorda had the opportunity to work on a messenger RNA program for a federal agency for an undisclosed virus that was not COVID-19. That mRNA product encoded antibodies against the virus. Blank says, “it was demonstrated that there was indeed in the lung the expression of antibodies.”
There are no upcoming events scheduled. Looking at other 10Q quarters it will be approximately the first week of November, company will issue a Pr when it is time as on other occasions
NO, Oxford University claims that the investigation into the death of a Brazilian volunteer has found no safety concerns.
474,532 in the BID at $ 0.20, we will go there to load
to save nasdaq rule of 1 $ in January, it seems that it will not be necessary ... and we will fly
2015 – IPIX SP begins year at $3.66 after peaking at $4.93 in December 2014
8/6/15 Mako hit piece immediately followed by bogus Rosen Class Action
2016 – IPIX SP begins year at $1.28
2017 – IPIX SP begins the year at $1.16 and closes year end at .73
2018 - 88M shares traded
-A then record amount of 55M or about 63% of the entire year total was traded in the last 4 months which was needed to compress IPIX SP from .53 to .07
2019 – 124M (almost a 50% increase in volume from 2018)
- May 2019 alone was 23M to negate the Alfasigma announcement
- YTD through October was 94M and 30M in the last 3 months to compress further down to .05 SP. NR had successfully crippled IPIX down to 5 cents a share making capital extremely expensive and dilutive for any science advancement.
2020 – A successful Phase 1 on B-IBD UC using BDD delivery system gives hope of a future licensing deal into a huge IBD market but then…….A worldwide pandemic strikes that no one saw coming INCLUDING the criminal cabal (also referred to as Non Retail or NR). An even bigger surprise is that our little baby bio investment IPIX’s Brilacidin, turns out to have far superior antiviral capabilities versus ANY other drug known to mankind against the CV19 virus and it not only reduces the overall viral load but kills the CV19 virus on contact, reduces inflammation and modulates the human immune response. Now back to the numbers!
2020 first 9 month volume is 524M. Note at this rate IPIX volume will be 699M in 2020 or ALMOST 6 TIMES THE VOLUME OF 2019. I personally believe that the last 10 weeks of volume in 2020 will be far greater than this rate due to milestone achievements discussed below.
Note that September of 2019 IPIX shareholders voted 90% in FAVOR of approving an increase in Authorized Shares from 300M to 600M. IMO this was an extremely strong vote of confidence that a vast majority of IPIX shareholders were in for the LONG haul. This shareholder confidence in IPIX science and management made it clear that very few IPIX investors were selling any of their position at these artificially compressed prices and by knowing what the own would not be selling under a several dollar SP. The criminals/NR know this very well and thus the comment that they are between a rock and a hard place.
A couple of examples of criminally compressed stocks that saw a sudden increase as NR lost control of SP and their naked position was forced into a squeeze.
- AMRN SP went from $3 to $26 in a very short period of time.
- OSTK SP was $2.23 this March and hit a peak of $123.00 this August. Does anyone on this board believe OSTK improved their business model by a factor of 55X over a brief few month period?
The entire contents above are simply proof points of criminal manipulation by NR but IMO IPIX will ultimately be valued based on their science making it through FDA trials and ultimately distributed successfully to the market to treat disease. My track record on predicting timing of events has not been great as I continue to be surprised at how long it takes to advance the science through FDA trials but with that said I believe we are getting very close to hitting some very huge milestones that will continue to de-risk our investment and bring life-saving drugs to the market. I am expecting to see:
In 30 days or less – FDA IND Approval and separately a Preprint of the RBL Peer Review paper.
In 45 days or less – Initiation of B-CV19 Human Trials
In 60-90 days – Interim Human Trial Results, Emergency Use and Compassionate Use approval. Major industry and investor exposure. Multiple media exposure in print, social media, television, radio discussing the treatment that kills CV19.
1stH 2021 – Large government order and/or government grant for volume shipment of Brilacidin for the masses in parallel with a Phase3 B-CV19 trial. International distribution partnership for B-CV19 to cover non-US demand. Separately a B-IBD UC Phase 2 trial kicks off as Brilacidin is further positioned as a franchise drug used for many different instances.
2ndH 2021 – IPIX will most likely have been already Up Listed off of the criminally controlled OTX to a legitimate exchange. Throughout 2021 the criminals will be scrambling to cover their naked position as an EPIC SHORT SQUEEZE takes place starting in the $2-4/share range but really kicking in the $5-$20 range. Remember that the criminals need REAL LONGS to sell REAL SHARES for them to cover their naked positions. IMO it will not be uncommon to see trading days where IPIX is trading at 10M+ shares daily and go up in $1 plus increments on days where no announcements are made. See the above OSTK example for both the magnitude of the SP increase and the short period of time that this could take place
and going up MRNA, SRNE, GILD, REGN ... all except
It was not 23
it seems so, let's see ...
what does not make sense is to publish news and the price to be below that day
and I don't believe in ghosts
PPS under the latest PR,
the truth ... depressing
pps same as October 2
remdesivir, dexametasona ... and an "experimental" treatment
looking at L2?
84000 CDEL at 0.23 is nothing
ASK very thin
LOL 0.27
we wake up?
He should take the medicines he recommended for other patients and those home "remedies"